Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

NCT05216432 is registered in ClinicalTrials.gov with Relay Therapeutics, Inc. as lead sponsor.

NCT NCT05216432
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05216432 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Lead sponsor
Relay Therapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
December 8, 2021
Completion date
April 30, 2027
Enrollment
930 (estimated)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, breast cancer, her2-negative breast cancer, metastatic breast cancer, pik3ca mutation, solid tumor, adult, unresectable solid tumor